This company seems to have been delisted
Reason: Acquired by AstraZeneca
Last recorded trade on: April 26, 2024
Source: https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.htmlherapy%20ambition.
Reason: Acquired by AstraZeneca
Last recorded trade on: April 26, 2024
Source: https://www.astrazeneca.com/media-centre/press-releases/2024/acquisition-of-gracell-completed.htmlherapy%20ambition.
Gracell Biotechnologies
GRCL
9,38 €
Share price
0.00%
Change (1 day)
172.99%
Change (1 year)
Categories
Gracell Biotechnologies (GRCL) - Net assets
Net assets on the balance sheet as of September 2023 : €0.20 Billion
According to Gracell Biotechnologies's latest financial reports the company has €0.20 Billion in net assets.
A company’s net assets is the sum of its assets minus the sum of its liabilities.
Gracell Biotechnologies - Net assets on balance sheet (from 2019 to 2023)
Net assets by year
| Year | Net assets | Change |
|---|---|---|
| 2022-12-31 | $€0.18 B | -26.56% |
| 2021-12-31 | $€0.25 B | 147.84% |
| 2020-12-31 | $€0.10 B | 213.12% |
| 2019-12-31 | $€32.63 M | 10673.1% |
| 2018-12-31 | $€0.3 M |
Net assets for similar companies or competitors
| Company | Net assets | differencediff. | Country |
|---|---|---|---|
 | €0.22 B | 7.44% | 🇺🇸 USA |